Philadelphia, PA
If you’re attending the 2025 IO Summit, don’t miss the chance to connect with Ncardia. We’re bringing our latest iPSC-based platforms and insights to Philadelphia — primed to support the next wave of innovation in immuno-oncology.
Whether you’re tackling tumor modeling, immune cell interactions, or therapeutic screening, our discovery services and human-relevant iPSC models can help you move forward with greater confidence.
Let’s explore how iPSCs are reshaping the future of cancer research.
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.
Learn More About IO Summit 2025